Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects

NCT01273532 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT01273532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01273532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
March 31, 2011
Enrollment
30 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer